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According to estimations made by the Central Brain Tumor Registry of the USA (CBTRUS), 17 000 people in the USA developed glioblass
toma multiforme (GBM) during 2006.1 GBM is the 
most aggressive stage of glioma. Even with the use of 
surgery and radiotherapy, this disease presents a rapid 
evolution and the first relapse occurs within the first 
year of diagnosis.2s8 The maximum survival time obs
served for people after first relapse and with surgery 
plus temozolomide is about 8 months. This survival 
time presents a poor quality of life. Due to the rapid 
progression of the disease, the patient falls into a coma 
during the last months of its evolution.2s8
One of the modern theories of this relapse is attribs
uted to the persistence of tumor stem cells that migrate 
towards healthy brain tissues. The tumor aggressiveness 
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BACKGROUnD: Glioblastoma multiforme (Gbm), the most aggressive glioma, presents with  a rapid evolution 
and relapse within the first year, which is attributed to the persistence of tumor stem cells (tSc) and the escape 
of immune surveillance. mixed leukocyte culture (mlc) cytoimplant has been shown to function as a power-
ful intratumor pro-inflammatory cytokine pump. tumor b-cell hybridoma (tbh) vaccines have been shown to 
function as antigen-presenting cells. We evaluated the toxicity and efficiency of each treatment alone and in 
combination. 
PATIEnTS AnD METHODS: in an open study, 12 consecutive patients were evenly divided into 3 groups, each 
group receiving 3 different treatments. patients in Group 1 were treated, after diagnosis, with debulking surgery 
(dS)+radiotherapy (rx), and after the first relapse underwent dS+mlc treatment. patients in Group 2 were 
similarly treated but after the first relapse underwent dS+mlc+tbh. finally, patients in Group 3 were similarly 
treated but after the first relapse underwent dS+tbh. nestin pap stain assessed tSc participation in tbh.
RESULTS: treatment with mlc had strong and rapid therapeutic effects, but was limited in duration and induced 
various degrees of brain inflammation. treatment with mlc+tbh acted synergistically, provoking a rapid, strong 
and lasting therapeutic response but also generating different degrees of brain inflammation. a lasting therapeu-
tic effect without generating high degrees of brain inflammation occurred in patients treated with tbh vaccine 
alone.
COnCLUSIOn: tSc vaccine consisting of tbh alone seems to have potent adjuvant reactions overcoming both 
persistence of tumor stem cells and immune escape of Gbm without provoking an encephalitic reaction.
is determined not only by the high tumor growth rate, 
but by the local and systemic immune suppression ins
duced by this tumor as well.9s21 
Patients with GBM present with decreased cellular 
and humoral immunity. This is particularly observed 
through the analysis of a decreased response to coms
mon antigen skin tests (candidin, tuberculin, etc.), as 
well as the poor response of circulating lymphocytes to 
stimulation with phytohemaglutinine (PHA). The pros
duction of antibodies to the tetanus toxin and to the flu 
vaccine is also diminished.16s21
This deficiency in the general immune response is 
thought to be induced by antinflammatory tumor facs
tors, mainly by transforming growth factor b (TGFb).16,17 
The specific lack of immune response against GBM is 
attributed, first, to the above described general immune 
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deficiency, and second, to the tumor cell lack of the mas
jor histocompatibility complex (MHC)18,19 and costims
ulatory molecules. Both phenomena interfere with the 
recognition of tumor cells as malignant cells by CD4 
and CD8 lymphocytes.16s21
Over the last twenty years, diverse immunotherapy 
protocols have been developed. As common features, 
these treatments involve the surgical reduction of tumor 
mass followed by local or systemic treatment with acs
tive or passive immunotherapy, nonsspecific stimulants 
(BCG vaccines, Corynebacterium parvum, and others), 
LAK cells implants, TIL cells, modified lymphocytes or 
fibroblasts associated or not with leukins or other bios
logical response modifiers, monoclonal antibodies alone 
or in conjunction with drugs. Despite the good results 
obtained in animal models, few of these approaches have 
produced truly significant results in clinical trials.21s43
Since 1997, our group applied, under a compassions
ate basis, two of these protocols: 1) The cytoimplant of a 
mixed lymphocyte culture (MLC) in the tumor lodge, a 
technique developed by Granger,44 discoverer of tumor 
necrosis factor and 2) systemic vaccination with a glios
ma cell Bslymphocyte hybrid (TBH). Each therapeutic 
procedure was applied separately or in association.45,46 
These methods were chosen based on previous animal 
experience, as well as our own therapeutic results, and 
those observed by other researchers in the treatment of 
human pancreatic cancer,44,47 a tumor that presents with 
similar immune features: high aggressiveness related to 
the high production of TGFb and the tumor cell lack 
of MHC molecules as well as their corresponding cos
stimulatory molecules.
Chang et al used MLC cytoimplant to treat stage Is
II pancreatic cancer44 with promising results. Its mechas
nism of action is attributed to the production of a strong 
primary graft vs. host rejection which begins to operate 
as an intratumor powerful TH1 leukin pump.44,47,48 A 
TBH vaccine was used to treat different tumors. This 
is an autologous cell hybrid formed by the fusion of aus
tologous tumor cells with autologous Bslymphocytes. 
Vaccination with this cell hybrid produces a specific 
antitumor reaction, which takes 45 to 60 days to be des
tected in the blood.45s49
As was proved for the treatment of pancreatic cancer 
and breast cancer,47,48 the association of MLC and TBH 
can elicit a synergistic effect improving their therapeutic 
outcome. The explanation for this synergistic effect can 
be summarized as follows: the action of TBH is pros
moted by the leukins generated by the reaction of the 
MLC, which also shortens its reaction time, generating 
a stable effector response (TH1).
The present report summarizes our experience uss
ing these two methods (as a single biologic agent or a 
combination of both), with special emphasis on their 
feasibility, toxicity and possible therapeutic benefits.
PATIEnTS AnD METHODS
The patients included in the present study, who were 
recruited between 1997 and January 2004, were males 
or nonspregnant females with a positive diagnosis of 
single and completely resected first or second relapsing 
GBM. The positive GBM diagnosis was performed by 
an experienced neuropathologist after the analysis of 
the resected surgical piece. The pathological analysis of 
the surgical piece met the three morphological criteria 
established by the WHO: a high degree of gliomorphic 
cytological malignancy, necrotic areas and high vascus
larization of the central part of each live cell tumor mass 
(Figures 1, 2).2,3 In addition, vimentin and glial fibrilliay 
acidic protein (GFAP)  (Zymed, San Diego, USA) ims
munoperoxidase stain were positive (Figure 3, 4). As an 
additional study, a nestin (R&D System, Grand Island, 
USA) immunoperoxidase was performed to assess the 
presence of tumor stem cells.9
Previous treatment of the primitive tumor included 
total surgical resection and a complete 3D radiotherapy 
scheme. At the beginning of treatment, the patients’ clins
ical performance met the ECOG 0s3 criteria40 and the 
spectroscopic analysis of the postsurgical MRI  showed 
no remaining tumor mass. These patients had not res
ceived radios or chemotherapy for at least a month prior 
to initiation of their immunotherapy regimen. Immune, 
cardiac, hepatic, respiratory and renal functions were 
preserved and there was no second active neoplasias, 
and no active viral or bacterial infection or visceral mys
cosis at the time of admission to the clinical trial. All 
patients provided signed, informed consent.
Twelve consecutive patients were evenly divided into 
3 groups, each receiving a different treatment. The first 
four patients (Group 1) were treated, after diagnosis, 
with debulking surgery (DS)+radiotherapy (Rx) and 
after first relapse, they underwent DS + MLC treats
ment. The next four patients (Group 2) were similarly 
treated but after first relapse underwent DS+MLC 
treatment+TBH vaccination. The last four patients 
(Group 3), after the first relapse were similarly treated, 
though they only underwent DS+TBH vaccination. 
MLC treatment: In this procedure, which has been 
previously described,44,47,48 a nonsrelated donor was 
selected and peripheral mononuclear cells (MNC) 
were collected from the donor and patient by apheresis 
(Cobe Spectra, Chicago, USA). MNC were purified 
and washed; the patient’s MNC were irradiated and 
used as a challenge to activate donor MNC during a 
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Figure	3.	Brown spots show vimentin pap positive stains of the 
same biopsy described in Figure 1. arrows show positive stain 
spots.
Figure	1.	High magnification of recurrent glioma anatompatholob
gic study from patient shown in Figure 7. Solid arrows show 
different nuclear shapes characteristic of this highly gliomorphic 
cytology. empty arrows show the high degree of vascularization 
present in those GBm patients. (H&e stain).
Figure	2.	White stars show highly gliomorphic cytology 
(gliomorphic cytologic malignancies). Black stars show necrotic 
areas from the same biopsy described in Figure 1.
Figure	4.	Glioblastoma multiforme (GBm), glial fibrilliay acidic 
protein (GFap) pap immunostain.
threesday mixed leukocyte culture. The activated cells 
were implanted into the tumor lodge after the neuros
surgery in a fibrin cloth performed with a commercial 
kit (Tissucol, BaxtersImmune, Chicago, USA). 
The tumor specimen extracted during surgery was 
divided into two parts, one part used for pathological 
studies and the other, processed as an antigen. The half 
tumor sample processed as antigen was mechanically 
dissociated to a single cell suspension. This cell suspens
sion was washed, the gradient purified and seeded in 
DMEM (Gibco, Grand Island, USA) enriched with ins
sulin and epidermal growth factor. Nonsfetal calf serum 
or human serum was added to this culture medium.
Development of TBH: In this procedure, which has 
been previously described,46 the patient’s mononuclear 
lymphocytes were obtained by apheresis (Cobe Spectra, 
Chicago, USA). B cells were purified from this monos
nuclear cell sample by negative selection (Stem Sep Kit, 
Stem Cell Technology, Vancouver, Canada). The B cells 
were cultured in a DMEM (Gibco, Grand Island, USA) 
enriched with IL6 (Stem Cell Technologies, Vancouver, 
Canada) and IL4 (Stem Cell Technologies, Vancouver, 
Canada) medium for three days. Tumor cells were fused 
with activated Bscells using PEG (Merck, Munich, 
Germany), thereby generating a TBH autovaccine. The 
immunizations were given by intraslymph node injecs
tion every three weeks upon medical indication.
For quality control, microbiological studies were 
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conducted on samples taken from apheresis products, 
from selected cells, and from the final product of each 
culture to detect contamination by bacteria, fungus or 
virus. If any sample proved positive, the final product 
was treated with antibiotics and/or antimycotics acs
cording to the in vitro sensitivity of the contaminants 
until negativization of culture; otherwise it was diss
carded and the procedure repeated. A double immune 
stain was performed with antisCD 19 and antisvimens
tin to corroborate that the hybrid cell had been formed. 
A nestin (R&D Systems Inc.) immunoperoxidase stain 
was performed to assess the contribution of tumor stem 
cells as a component of the TBH hybrid.
Clinical controls and follow-up: During the week pres
vious to any treatment, the patients went through sevs
eral controls: a complete clinical history with particular 
emphasis on the neurologic examination, clinical analys
ses, electrocardiogram, and pulmonary function, as well 
as immune analyses. The ECOG index was established 
according to international standards.49 An MRI of the 
brain was also obtained.
Patients were controlled by the same physician once 
a week during the first trimester of treatment, every fifs
teen days for the following six months, and after that, 
once a month until the end of two years of treatment. At 
each examination, the clinical history was updated and 
lab tests were performed. The immune response against 
the tumor was analyzed prior to each vaccine; then, afs
ter the vaccination plan was completed, the immune res
sponse was analyzed every month for the first year, and 
every three months thereafter. The data regarding toxic 
reactions were specially reported to the safety commits
tee. Patient survival was monitored monthly.
Criteria of tumor response: The two main criteria were 
survival, evaluated by telephone communication once a 
month, and tumor mass presence, assessed at 6 months 
post beginning of relapse treatment (MLC cytoimplant 
for Groups 1 and 2, or first TBH vaccine immunization 
for Group 3). For the second criterion, three degrees of 
response were established: 1) complete remission (CR): 
no detection of any tumor mass assessed by MRI and 
spectrometry analysis of MRI images; 2) partial remiss
sion (PR): minimal tumor mass present at the borders 
of the original tumor lodge (the total tumor mass press
ent at evaluation time should be smaller than 50% of the 
original tumor mass); and 3) progressive disease (PD): 
at the evaluation point there was a relapse of the original 
tumor mass or new metastasis in the CNS larger than 
50% of original tumor mass. Patients who presented as 
CR or PR were considered “responders” and those who 
presented as PD were “nonsresponders”.
Evaluation of toxicity: Adverse events were evaluated 
by the “Common Terminology Criteria for Adverse 
Events (AE), 2004” developed by NIH. The definitions 
are available on the web at http://ctep.cancer.gov/res
porting/ctc.html. 
Immune evaluation: The immune response against 
the tumor was evaluated through a DTH reaction and 
the lymphocyte proliferation index (LPI).50 The DTH 
reaction is an intradermal reaction performed using 105 
irradiated autologous TBH cells. Cells were suspended 
in 0.1 cc buffer salt solution (BSS) and intradermally 
injected. As controls, 105 irradiated heterologous TBH 
cells were used. For the LPI,50 the MNC taken from 
a 20 cc blood sample from the patient were layered in 
a FicollsHypaque gradient (Beckman Coulter Inc., 
Fullerton, CA, USA) and spun for 10 minutes at 300 
G. These cells were seeded in a 96swell plate in TC 199 
to which different immunogenic substances were added: 
1) MNC without stimulus; 2) MNC without stimulus 
+ patient’s serum; 3) MNC vs. patient TBH cells, and 
4) MNC+patient serum vs. patient TBH cells. Each 
assay was carried out in duplicate with 5×103 MNC 
seeded in each well. After 96 hours of culture, the tos
tal number of cells was counted using an automatic cell 
counter.
LPI was calculated as the rate between the number 
of challenged MNCs over the number of nonstimulats
ed MNCs. If the index was lower than 0.7 the immune 
system tolerated the tumor. If this index proved higher 
than 1, the immune system had developed an antitumor 
effector reaction against the tumor.
Statistical data analysis: The KaplansMeyer test 
was used to evaluate the data on survival. The tumor 
response, immune response, and toxicology data were 
analyzed using analysis of variance. We looked for P vals
ues lower than 0.01 as statistically significant.
RESULTS
We recruited four patients for each group. Clinical 
conditions and treatment results are summarized in 
Table 1. 
GBM cell and TBH culture: Contrary to what occurs 
in most primary cultures obtained from surgical pieces 
of carcinomas and sarcomas, the mechanical dissocias
tion of the GBM tumor mass produced an almost pure 
suspension of malignant cells characterized by nuclear 
and cytoplasmic polymorphism. After about 15 days, 
the number of cells in culture experienced a dramatic 
drop of about 97% to 99% from the initial amount. 
These remaining cells were able to grow in a sustains
able manner and established in culture in all 12 of the 
treated patients. These cells grew during 15 days until a 
critical tumor cell mass was obtained to be hybridized 
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Table	1.	Clinical conditions and results.
Patient Age Sex Second	Surgery Chemotherapy Radiolotherapy ECOG Therapy Survival	after	recurrence	(months) Dead
li 49 F yes 1 1 3 mlC 2 yes
ey 51 m yes 0 1 2 mlC 6 yes
Sa 46 m yes 0 1 1 mlC 15 yes
mo 65 F yes 0 1 2 mlC 3 yes
Sr 36 m yes 0 1 1 m+T 6 yes
ar 71 F yes 0 1 3 m+T 8 yes
pi 58 m no 0 0 1 m+T 15 yes
Vi 52 m yes 0 1 2 m+T 7 yes
Va 51 m no 0 1 1 TBH 18 yes
rz 72 m yes 1 1 3 TBH 14 no
Gz 48 F yes 0 1 1 TBH 25 yes
Ss 33 F yes 0 1 1 TBH 37 no
mlC: mixed leucocyte cytoimplant; TBH: tumor Bbcell hybridoma vaccine; m+T: mlC+TBH. For chemotherapy, 1=complete standard therapy, 0=no chemotherapy. For radiotherapy, 1=complete dose of radiation, 
0=no radiotherapy. 
with autologous B lymphocytes of the patient. 
The yield of this fusion was 14%, with respect to the 
original amount of cells used. This cellular population 
proved to be homogeneous, with monomorphic and lats
eralized nuclei and large starsshaped cytoplasm (Figure 
5). The primary double immune staining of these cells 
with antisCD19 and antisvimentin allowed us to ess
tablish its hybrid character. Afterwards, four of these 
cell lines preserved in culture were stained with nestin, 
all being positive for this staining, hence certifying the 
GBMsstemscell origin of this hybrid (Figure 6).
Immune response: For patients in Group 1, the MLC 
cytoimplant generated a rapid effector response 15 days 
after the procedure was completed, in the responder 
as well as in the nonsresponders. This response lasted 
until the fourth month in the responder patients, and 
stopped at three weeks in nonsresponder patients. In 
two patients, we observed a clear autoimmune response 
that generated encephalitis degree 2 according to the 
“Common Terminology Criteria for Adverse Events 
(AE), 2004” developed by NIH.
For patients in Group 2, the MLC cytoimplant fols
lowed by six immunizations with TBH respectively 
produced a marked effector in vitro response 15 days afs
ter the completion of the cytoimplant. In the responder 
patients, the response continued, increasing steadily for 
the duration of the entire treatment. In these patients, 
the autologous serum continually acted as a promoter of 
the in vitro effector reaction. Although all the patients 
treated were responders, two showed a remarkable ens
cephalitic autoimmune reaction above degree 3s4 that 
obliged us to suspend the MLC treatment.
For patients in Group 3, the six immunizations with 
the TBH autovaccine showed in the four responder 
patients the appearance of an effector reaction in the 
peripheral lymphocytes around the third month of 
treatment. This response lasted for three more months. 
The presence of autologous serum showed a dual effect. 
During the first three months, it had inhibitory effects 
on the proliferation assay. After this 3smonth period the 
patients developed an effector response. The expected 
autoimmune inflammatory reaction was degree 1 in 1 
of 4 patients and absent in 3 of 4.
Tumor response and survival: In Group 1 (treatment 
with MLC alone) 3 of 4 were responders (CR+PR) and 
1 of 4 had progressive disease (PD). The median survivs
al of this group after MLC treatment was 4.5 months. 
In Group 2 (treatment with MLC and six immunizas
tions with TBH), 4 of 4 were responders (CR+PR). 
The median survival of this group was 9.5 months after 
MLC treatment. In Group 3 (immunization with autos
vaccine TBH alone), 3 of 4 were responders (CR+PR). 
The median survival of this group was 25 months after 
the first immunization. The chissquare was 2.87 and 
had a significance level of P=0.11. (Figures 7, 8, 9 and 
10)
Adverse events and side effects: Patients in Groups 1, 
2 and 3 developed fluslike symptoms and hyperpyrexia 
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Figure	5.	Single TBH cell in tissue culture, Giemsa stained.
Figure	6.	note the cytoarchitectural stain of nestin positive reaction inside two large 
hybrid cells.
Figure	7.	mri of preboperated recurrent 
GBm patient of group 3 (treated with TBH 
alone).
Figure	8.	mri of patient in Group 3 
(treated with TBH alone) three years after 
treatment.
from 37.5 to 39.5ºC during the first 24s72 hours posts
vaccination (Table 2). The severity of the fever did not 
seem to have a direct correlation to the favorable progs
nosis of the therapeutic response. Eight of 12 patients 
presented with nausea or gastrointestinal upset assos
ciated with the use of nonssteroidal analgesics. These 
symptoms were resolved either by discontinuing the 
medication or combining it with metoclopramide. Of 
the patients in Groups 1, 2 and 3, 2 of 4, 4 of 4 and 
1 of 4, respectively, experienced transitory episodes of 
hypotension during the first 60 hours after the cytoims
plant or the immunization with TBH. The patients res
quired no therapy. Encephalitic autoimmune reactions 
were present in 50% of the patients treated with MLC 
cytoimplants (Group 1, 2 of 4 and Group 2, 2 of 4). No 
cardiac, respiratory, kidney, blood toxicity or clotting 
disturbances were observed in any group.
DISCUSSIOn
According to Gatcombe8 “patients diagnosed with glios
blastoma multiforme (GBM) have a notoriously grim 
prognosis; median survival is only 13 months with muls
timodality treatment.4 The current standard of care for 
these patients is surgical resection followed by concurs
rent radiation and temozolomide (TMZ), and then by 
adjuvant TMZ. This regimen has been demonstrated 
to improve median survival by a modest 2.5 months.5 
Thus, new interventions are desperately needed for pas
tients diagnosed with GBM.”
The discovery of the high sensitivity of GBM to 
epidermal growth factor (EGF),21s24 brought the use of 
13scissretinoic acid, which is an inhibitor of the EGF 
receptor transduction.22 The good results observed led 
to the use of monoclonal antibodies (MAB) directed 
against this receptor.23,24 Both treatments produced an 
effective increase in the survival rates of GBM patients. 
This approach only applies to newly diagnosed patients 
and its action is limited in time and seems to extend but 
not prevent the relapse of the tumor.
The fact that GBM cells present clearly identifiable 
antigen molecules, which may be the target of an ims
mune system attack, inspired several immunotherapy 
approaches. These antigens, called tumorsassociated 
antigens (TAA), are molecules different from the nors
mal structures or expressed in an abnormal amount or 
corresponding to the structure of an age different from 
the individual’s chronological age.18 
Different active and passive immunization techs
niques have been successfully used in animal models. 
For years, however, these techniques failed to produce 
the same successful outcome in human trials.16s43 The 
high levels of transforming growth factor b (TGFb) 
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Figure	9.	immune evolution of lymphocyte proliferation index analysis of Figure 1 patient.
Figure	10.	Kaplanbmeyer analysis of GBmbrelapsed patients after different treatments. Group 1: mlC 
treatment; Group 2: mlC + TBH; Group 3: TBH.
produced by this tumor and the poor expression of cos
stimulatory molecules on GBM cell membranes seem 
to be the major causes of immune therapy’s failures.16s20 
TGFb is the most important secretion of GBM. This 
cytokine causes immune suppression, typical of GBM, 
as well as inductions of immune tumor tolerance.16s18 
The surgical removal of the TGFb source supports these 
facts. Patients may show a recovery of their immunity 
during the first month postsurgery. 
Using the therapeutic window of postsurgical ims
mune recovery, several adoptive immunotherapeutic aps
proaches have been used. There are therapies aimed at 
enhancing the local immune status26s36 by the infusion 
of lymphokinesactivated killer (LAK) cells or cytokines, 
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such as interleukins2 (ILs2)26s32 or interleukins12 (ILs
12)33, or the infusion of granulocyte macrophage colonys
stimulating factor (GMsCSF)34,35 in the tumor lodge afs
ter a debulking surgery. However, these techniques were 
reported to have transient effects and to produce toxic 
side effects.
Granger’s team developed an adjuvant treatment 
based on the implant of a mixed culture of leucocytes 
(MLC) in the tumor lodge (cytoimplant).44 This MLC 
was generated by mononuclear cells (MNC) of an uns
related donor against the patient’s inactivated MNC. 
MLC cytoimplant produced a powerful Th1 leukin 
pump in the surgical lodge that, due to the special chars
acteristics of the GBM and the brain, was surrounded 
by tumor cells, which diffusely infiltrate the normal tiss
sue. The Th1 pump favored the access of the patient’s 
effector lymphocytes, which learned how to act not only 
against the heterologous tumor graft, but also against 
the remaining tumor cells.44,47,48 In an early trial using 
this approach, 2 of 9 recurrent GBM patients achieved 
3 years diseasesfree survival. This therapeutic approach 
was also applied in patients with stage II pancreatic tus
mors achieving similar successful results.44
Based on the presence of TAA and the poor cos
stimulatory expression of GBM cell membrane, several 
vaccine protocols were developed.36s43 They used peps
tides, dendritic cells or irradiated cells either alone or in 
combination with dendritic cells to improve the antigen 
presenting function of the tumor antigen. 
Peptide vaccines induced specific antigen immunity 
against specific TAA. There was poor or no cross res
activity against other TAA elicited by this type of vacs
cine.36s43 Moreover, those antigens belonged to differens
tiated forms of the GBM cells but were not present on 
the tumor stem cells.8s15 Therefore, the GBM stopped 
producing cells to carry on those antigens and devels
oped new tumor cells free of TAA1. This biological 
condition was named “tumor editing”. 
To avoid tumor editing, new vaccines used whole 
tumor cells. Three main approaches have been used. 
First, dendritic cells boosted with whole tumor cells,36,37 
GBM lysate,38 several specific membrane antigen39,40 or 
tumor nucleic acids.41 These techniques were applied 
with relative clinical success, but only had positive theras
peutic effects in newly diagnosed patients. A second aps
proach was the use of genetically modified tumor cells 
producing an effector that induces leukins35; and third, 
dendritic GBMsfused cells.43 Those approaches showed 
some extra effectiveness as compared to the peptide vacs
cine approach but, even when they prolonged diseases
free survival time, they failed to prevent a relapse. The 
main cause of this failure (relapse prevention) may be 
attributed to the lack of effectiveness to elicit an antitus
mor stem cell reaction which, in time, developed a more 
primitive undifferentiated GBM lacking the previously 
showed TAA as well as remaining chemoresistant.11s14
Table	2.	adverse events in the 12 patients included in the study.
Toxicity
Patient Flu-like	Syndrome
Brain	
immflammation Kidney Lung Cardiovascular Gastrointestinal	 Hematology Others
li 0 0 0 0 0 0 0 0
ey 0 2 0 0 0 0 0 0
Sa 0 2 0 0 0 0 0 0
mo 1 4 0 0 0 0 0 0
Sr 1 4 0 0 0 0 0 0
ar 1 0 0 0 0 0 0 0
pi 1 2 0 0 0 0 0 0
Vi 0 2 0 0 0 0 0 0
Va 0 1 0 0 0 0 0 0
rz 1 0 0 0 0 0 0 0
Gz 1 1 0 0 0 0 0 0
Ss 0 0 0 0 0 0 0 0
numbers indicate toxicity degree, where 0 represents no adverse event observed; 1b2 means mild adverse events and 3b4 means important adverse events observed.
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In conjunction with these therapeutic developments, 
in 1996 our group started to use Granger’s technique 
to treat GBM patients. After the first four treated pas
tients, this therapy was combined with a tumor vaccine 
we have developed in an attempt to improve the res
sponse rate of the MLC cytoimplant.45,46 As mentioned 
above, either the poor presence or the lack of costimus
latory molecules of the tumor cells induces tumor ims
mune tolerance.18s20 To overcome this problem, we used 
a tumor hybrid vaccine produced by the fusion of the 
patient’s tumor cells and autologous activated B cells 
(TBH). Tumor cells provide the TAA and the B cells 
provide MHC I and MHC II, costimulatory and ads
hesive molecules.45,46 This hybrid of fused cells vaccine, 
unlike the dendritic GBM fused cells vaccine, can grow 
in vitro for a long time, allowing patient immunization 
with the same cell in a sufficient amount for the whole 
vaccination program.43,45,46 
Chen et al. showed that TAA are present in GBM 
tumor stem cells.15 We hypothesize that, as was res
ported, even when TAA are weak, when presented in a 
TBH cell shape, they could be easily recognized by the 
lymph node dendritic cells, thus generating a specific 
cytotoxic reaction with effective antitumor activity. 
Comparing the therapeutic and the immune results 
described in the corresponding section, we observed 
that the MLC treatment itself produces strong and raps
id therapeutic effects. However, its action seems limited 
in time and may provoke an important, hard to treat, 
autoimmune reaction against healthy brain parenchys
ma. Combining this treatment with TBH vaccine pros
longs the immune activity against the glioma but, again, 
the patient could suffer an autoimmune reaction in the 
brain.
The inflammatory response observed in 4 of 8 pas
tients in both groups (Groups 1 and 2) seemed to be 
the mainly responsible for the failure of the longsterm 
duration of the earlier obtained successful results. This 
brain inflammatory response was attributed to an uns
wanted side effect of the MLC cytoimplant. Therefore, 
it was decided to treat a third group only with 6 TBH 
immunizations after the debulking surgery of relapsed 
GBM. The immune response of TBH alone seems to be 
slower than either MLC alone or combined with TBH 
but seems to be more effective and less toxic. 
The quality and extent of the autoimmune inflams
matory reaction observed in GBM patients treated with 
MLC (alone or in combination with TBH), is more sigs
nificant than that observed in patients with other solid 
neoplasia treated with the same therapies. Pancreatic 
and breast cancer patients treated using a combination 
of MLC and TBH presented better tumor response 
and survival rates than those treated with either therapy 
alone.47,48 Moreover, in Groups 1 and 2, MLC alone or 
MLC combined with TBH, seemed to have no statistics
ly different effect on the survival time, in contrast with 
the longer survival time observed in Group 3, which 
only received TBH.
The outstanding results obtained with the use of 
TBH alone, compared with other pathologies, led to 
the idea that the greater success in the use of TBH was 
associated with the use of a tumor cell subsets. This ass
sumption was reinforced by the particular behavior exs
hibited by these cells in tissue culture. After the GBM 
tissue dissociation, a large number of polymorphic tus
mor cells were obtained. This cell culture suffered a dras
matic drop in its number. Only about 1% to 3% of the 
seeded cells survived. Surviving cells were a homoges
neous mass with monomorphic and lateralized nuclei, 
and with a starsshaped cytoplasm. The culture condis
tions lacked substances commonly used by other res
searchers such as fetal calf serum and fibroblast growth 
factor. It consisted only of DMEM medium enriched 
with human insulin and human epidermal growth facs
tor without any faetal calf serum or human serum sups
plementation. According to the work of Singh et al.,9,10 
this growth pattern is proper for GBM stem cells.
At the end of the 1990s, tumor stem cells were idens
tified as tissue cells in which those mutations necessary 
for the transformation of stem cells into tumor cells 
take place. They could, in experimental models, repros
duce the total tumor mass while the rest of the GBM 
cells were unable to do so. For this reason they are cons
sidered responsible for tumor relapse after a successful 
debulking surgery. Moreover, the GBM stem cell popus
lation is particularly resistant to chemotherapy and ras
diotherapy.9s15 
Since this is a primitive cell, its antigenicity is differs
ent from that presented by the more developed stages 
of the tumor from which this cell originates. For this 
reason, those vaccines developed against the differentis
ated forms of a tumor are mostly effective for the cons
trol of these forms, but ineffective to attack the tumor 
stem cells and the mutated clones which differentiate to 
the previously mentioned forms. 
Singh et al9 have determined that there are two chars
acteristic GBM stem cell markers: CD 133 and nestin 
molecules. The first is a membrane protein and the secs
ond is a component of the neural stem cell and GBM 
stem cell cytoskeleton. Neither molecule is present in 
the differentiated stages of the tumor cells or in normal 
nerve cell tissue. The fact that hybrids react positively 
to nestin proteins allowed us to believe that the TBH 
cells are formed by tumor stem cells. The particular 
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pattern of GBM cells observed in our cultures is ass
sociated with a positive nestin stain observed in TBH. 
According to Singh et al.,40 both are univocal characters
istics of GBM stem cells and support our assumption 
that this particular TBH is formed by GBM stem cells. 
Our results suggest, as implied by other authors, that 
GBM stem cells may be used as a basis for a tumor vacs
cine.10,14,15 
In conclusion, a TBH GBM stem cellsbased vaccine 
seems to elicit a specific tumor immune reaction withs
out harming normal nerve tissue. This immune reacs
tion seems to be strong enough to control or destroy 
the growth of the remaining GBM stem cells diffused 
in the normal brain tissue, which is supported by the 
outstanding diseasesfree survival time with a minimum 
of toxicity observed in patients of Group 3. A larger 
trial is in progress to assess the veracity of these pres
liminary conclusions.
Acknowledgements
In memory of Dr. Molina H. The critical review of Mark 
Renneker MD and Henry Smilowitz PhD, the spiritual 
support of Ms Maricel Brandolino and Dr. Ernesto 
Goverman, the technical assistance of Ms Carolina 
Beascoechea, and the economic support of Fundación 
Regina Mater are gratefully acknowledged.
original research reportTumOr STem Cell VaCCine FOr reCurrenT GBm
Hematol Oncol Stem Cell Ther 1(1)     January 2008 hemoncstem.edmgr.com 13
1.	 Central Brain Tumor registry of the u.S (CBb
TruS) data 2005
2.	Burger pC, Vogel FS, Green SB, et al. Glioblasb
toma multiforme and anaplastic astrocytoma: 
pathologic criteria and prognostic implications. 
Cancer 1985; 56:1106b1111
3.	 nelson JS, Tsukada y, Schoenfeld D, et al. 
necrosis as a prognostic criterion in malignant 
supratentorial, astrocytic gliomas. Cancer 1983; 
52:550b554
4.	laCroix m, abibSaid, Tourney Dr, et al. a multib
variate analysis of 416 patients with glioblastoma 
multiforme: prognosis, extent of resection, and 
survival. J neurosurg. 2001; 95:190b198
5.	Stupp r, mason Wp, van den Bent mJ, et al. 
radiotherapy plus concomitant and adjuvant teb
mozolomide for glioblastoma. n engl J med. 2005; 
352:987b996 
6.	athanassiou H, Synodinou m, maragoudakis e, 
et al. randomized phase ii Study of temozolomide 
and radiotherapy compared with radiotherapy 
alone in newly diagnosed glioblastoma multiforme. 
J Clin Oncol 2005; 23(10):2372b2377
7.	Hou lC, anand Veeravagu BS, Ssu ar, et al. 
recurrent Glioblastoma multiforme: a review of 
natural history and management options. neurob
surg Focus (2006) 20 (4):e3
8.	Gatcombe H. advances in the management of 
glioblastoma multiforme: an expert interview with 
Dr renato la rocca from 2006 SnO. medscape 
hematologybOncology. 2007;10(1). Jan 2007 www.
medscape.com 
9.	Singh SK, Clarke iD, Terasaki m, et al. identificab
tion of a cancer stem cell in human brain tumors. 
Cancer res 2003; 63:5821b5828
10.	Singh SK, Clarke iD, Hide T, et al. Cancer stem 
cells in nervous system tumors. Oncogene. 2004; 
23(43):7267b73
11.	albHajj m, Becker mW, Wicha m, et al. Therab
peutic implications of cancer stem cells. Curr Opin 
Genet Dev. 2004;14(1):43b7
12.	Donnenberg VS, Donnenberg aD. multiple drug 
resistance in cancer revisited: the cancer stem 
cell hypothesis. J Clin pharmacol. 2005;45(8):872b7
13.	liu G, yuang X, Zeng Z, et al. analysis of gene 
expression and chemoresistance of CD133+ canb
cer stem cells in glioblastoma. molecular Cancer 
2006; 5:67
14.	Galderisi u, Cipollaro m, Giordano a. Stem cells 
and brain cancer. Cell Death Differ. 2006;13(1):5b11
15.	Chen l, Shen r, ye y, et al. precancerous Stem 
Cells Have the potential for both Benign and mab
lignant Differentiation. ploS One, 2007, 2(3): e293 
1b16 doi: 10.1371/Journal.pone.0000293
16.	naganuma H, Sasaki a, Satoh e, et al. Transb
forming growth factorb_ inhibits interferonbg 
secretion by lymphokinebactivated killer cells 
stimulated with tumor cells. neurol med Chir 1996; 
36:789b795
17.	 Fakhrai H, Gramatikova S, Safaei r. Downb
regulating of Transforming Growth Factor b as 
Therapeutic approach for Brain Tumors. Brain 
Tumor immunotherapy. editors liau lm, Becker 
Dp, Cloughesy TF, Bigner DD. Humana press, 2001; 
Chap 14: 289b299
18.	 parney iF, Hao C, petruk KC. Glioma imb
munology and immunotherapy. neurosurgery 
2000;46(4):778b91
19.	Tran CT, Wolz p, egensperger r, et al. Differb
ential expression of mHC class ii molecules by 
microglia and neoplasic astroglia: relevance for 
the escape of astrocytoma cells from immune 
surveillance. neuropathol appl neurobiol 1998; 
24(4):293b301
20.	 Wheeler CJ, Black Kl, liu G, et al. Thymic 
CD8+ T cell production strongly influences tumor 
antigen recognition and agebdependent glioma 
mortality. J. immunol. 2003; 171:4927b4933
21.	Wiesner Sm, Freese a, Ohlfest Jr. emerging 
concepts in glioma biology: implications for clinib
cal protocols and rational treatment strategies. 
neurosurg Focus. 2005;19(4):e3
22.	 Westarp me, Westarp mp, Grundl W, et al. 
improving medical approaches to primary CnS 
malignanciesbretinoid therapy and more. med Hyb
potheses. 1993; 41(3):267b76
23.	Kuan CT, Wikstrand CJ, Bigner DD. eGF mutant 
receptor Viii as a molecular target in cancer therb
apy. endocr relat Cancer. 2001; 8 (2):83b96
24.	yang W, Barth rF, Wu G, et al. Development 
of a syngeneic rat brain tumor model expressing 
eGFr Viii and its use for molecular targeting studb
ies with monoclonal antibody l8a4. Clin Cancer 
res. 2005; 11(1):341b50
25.	Klatzmann D, philippon J, Valery C, et al. Gene 
therapy for glioblastoma in adult patients: safety 
and efficacy evaluation of an in situ injection of reb
combinant retroviruses producing cells carrying 
the thymidine kinase gene of the herpes simplex 
type 1 virus, to be followed with the administrab
tion of glancicovir. Human Gene Therapy 1996; 
7:109b126
26.	van Herpen Cml, De mulder pH. loco regional 
immunotherapy in cancer patients: review of clinib
cal studies. ann Oncol 2000;11(10):1229b39
27.	 Tse VCK, Conley FK. immunostimulation and 
immunomodulation of Brain Tumors. Brain Tumor 
immunotherapy. edited by liau lm, Becker Dp, 
Cloughesy TF, Bigner DD. Humana press, 2001. 
Chap. 4:91b99
28.	 Fenstermaker r, Ciesielski m. immunotherab
peutic strategies for malignant glioma. Cancer 
Control 2004; 11(3):181b191 
29.	Fujimiya y, Suzuki , Katakura r, et al. injury to 
autologous normal tissues and tumors mediated 
by lymphokinebactivated killer (laK) cells generb
ated in Vitro from peripheral blood mononuclear 
cells of glioblastoma patients. J Hematother 
1999;8(1):29b37
30.	merchant re, ellison mD, young HF. immunob
therapy for malignant glioma using human recomb
binant interleukineb2 and activated autologous 
lymphocytes. a review of prebclinical and clinical 
investigations. J neurooncol 1990;8(2):173b88
31.	 merchant re, Baldwin nG, rice CD, et al. 
adoptive immunotherapy of malignant glioma usb
ing tumorbsensitized T lymphocytes. neurol res 
1997;19(2):145b52
32.	plautz G, Barnett G, miller D, et al. Systemic 
T cell adoptive immunotherapy of malignant gliob
mas. J neurosurg 1998; 89:42b51 
33.	Jean W, Spellman S, Wallenfriedman m, et al. 
interleukineb12bbased immunotherapy against rat 
9l glioma. neurosurgery 1998; 42(4): 850b857
34.	Wallenfriedman ma, Conrad Ja, Della Barre 
l, et al. effects of continuous localized infusion of 
granulocytebmacrophage colonybstimulating facb
tor and inoculations of irradiated glioma cells on 
tumor regression. J neurosurg. 1999; 90(6):1064b
71
35.	Graf m, Jadus m, Hiserodt J, et al. Developb
ment of systemic immunity of glioblastoma mulb
tiforme using tumor cells genetically engineered 
to express the membranebassociated isoform of 
macrophage colonybstimulating factor. J immunol 
1999; 163:5544b5551
36.	 Siesjo p, Visse e, Sjogren HO. Cure of esb
tablished, intracerebral rat gliomas induced by 
therapeutic immunizations with tumor cells and 
purified apC or adjuvant iFnbgamma treatment. 
J immunother emphasis Tumor immunol. 1996; 
19(5): 334b45
37.	Okada H, pollack iF, lieberman F, et al. Gene 
therapy of malignant gliomas: a pilot study of vacb
cination with irradiated autologous glioma and 
dendritic cells admixed with ilb4 transduced fib
broblasts to elicit an immune response. Hum Gene 
Ther. 2001;12(5):575b95
38.	pellegatta S, poliani pl, Corno D, et al. Denb
dritic cells pulsed with glioma lysate induce immub
nity against syngeneic intracranial gliomas and inb
crease survival of tumorbbearing mice. neurol res 
2006; 28(5):527b31
39.	yu JS, Wheeler CJ, Zeltzer pm, et al. Vaccib
nation of malignant glioma patients with peptideb
pulsed dendritic cells elicits systemic cytotoxicb
ity and intracranial Tbcell infiltration. Cancer res 
2001;61(3):842b7
40.	 Okada H, Tahara H, Shurin mr, et al. Bone 
marrowbderived dendritic cells pulsed with a 
tumorbspecific peptide elicit effective antibtumor 
immunity against intracranial neoplasms. int. J 
Cancer. 1998; 78 (2): 196b201
41.	ashley Dm, Faiola B, nair S, et al. Bone marb
rowbgenerated dendritic cells pulsed with tumor 
extracts or tumor rna induce antitumor immub
nity against central nervous system tumors. J exp 
med. 1997; 186(7): 1177b82
42.	liau lm, prins rm, Kiertscher Sm, et al. Denb
dritic cell vaccination in glioblastoma patients inb
duces systemic and intracranial Tb cell responses 
modulated by the local central nervous system 
tumor microenvironment. Clin Cancer res. 2005; 
K 11 (15): 5515b25
43.	Kikuchi T, akasaki y, irie m, et al. results of a 
phase i clinical trial of vaccination of glioma pab
tients with fusions of dendritic and glioma cells. 
Cancer immunol immunother 2001;50(7):337b44
44.	 Chang KJ, nguyen pT, Thompson Ja, et al. 
phase i clinical trial of allogeneic mixed lymphob
cyte culture (cytoimplant) delivered by endob
scopic ultrasoundbguided finebneedle injection 
in patients with advanced pancreatic carcinoma. 
Cancer. 2000;88(6):1325b35
45.	Guo y, Wu m, Chen H, et al. effective Tumor 
Vaccine Generated by Fusion of Hepatoma Cells 
with activated B Cells. Science, 1993; 263: 518b520
46.	 moviglia Ga, Development of tumor Bbcell 
lymphocyte hybridoma autovaccination. results 
of phase ibii clinical trial. Transfusion Sci 1996 17: 
643b649
47.	moviglia Ga, Gaeta C, iraola n, et al. Combinab
tion immunotherapy for pancreatic Cancer. prob
ceeding of american Society for Clinical Oncology 
2001; 20: 264a
48.	moviglia Ga, Gaeta Ca, abdelnur r, et al. Comb
bination immunotherapy for metastatic breast 
cancer. proceeding of american Society for Clinib
cal Oncology 2003, 22: 182
49.	Oken, m.m., Creech, r.H., Tormey, D.C., et al. 
Toxicity and response Criteria Of The eastern Cob
operative Oncology Group. am J Clin Oncol 1982, 
5:649b655
50.	moviglia Ga, lara p, Varela G, et al. ensayo de 
proliferación linfocitaria para el monitoreo inmub
nológico del paciente oncológico y su utilidad en 
el seguimiento de los tratamientos inmunomodub
ladores. archivos argentinos de alergia e inmub
nología Clínica 1999; 30 (2): 40
REfEREnCES
